Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.
Fiche publication
Date publication
janvier 2015
Journal
PloS one
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DEVILLIERS Hervé
Tous les auteurs :
Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O
Lien Pubmed
Résumé
Anti-synthetase syndrome (anti-SS) is frequently associated with myositis and interstitial lung disease (ILD). We evaluated prospectively, in a multicenter, open-label, phase II study, the efficacy of rituximab on muscle and lung outcomes.
Mots clés
Adult, Autoantibodies, immunology, Creatine Kinase, blood, Female, Humans, Immunologic Factors, therapeutic use, Male, Middle Aged, Myositis, drug therapy, Rituximab, therapeutic use, Treatment Outcome, Vital Capacity, Young Adult
Référence
PLoS ONE. 2015 ;10(11):e0133702